Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 50Recurrence 6Myelodysplastic Syndromes 4Neoplasms 2Leukemia, Myeloid 2Leukemia 2Hematologic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms by Histologic Type 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Infections 1Disease 1Blast Crisis 1

Interventions

Cytarabine 2venetoclax 1pembrolizumab 1obinutuzumab 1neratinib 1idelalisib 1ibrutinib 1gilteritinib 1Surveys and Questionnaires 1Positron Emission Tomography Computed Tomography 1Mitoxantrone 1Interleukin-15 1Gemtuzumab 1Daunorubicin 1CPX-351 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease × gilteritinib × Other hematologic neoplasm × Clear all
NCT06667973 2025-03-12

Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2 Not yet recruiting
80 enrolled
Other hematologic neoplasm

Disease, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡